🇺🇸

Distress Insolvency

· daily

US Corporate Distress Financial Stress SEC Filings — August 20, 2026

Three US-listed small-cap companies received critical exchange compliance notices within a week (August 14-20, 2026), revealing a concentrated wave of corporate distress. The most severe case is Nukkleus Inc. (T3 Defense/DFNS), which faces Nasdaq delisting after its stockholders' equity collapsed by $62.2 million quarter-over-quarter (from +$42.5M to -$19.7M) due to a massive fair-value warrant loss—marking the most dramatic financial deterioration among the filings. Ocean Power Technologies (OPTT) represents a rapidly resolved risk, having cured its NYSE American late-filing delinquency by filing its 10-K just one day after the cure period ended, demonstrating administrative diligence. BullFrog AI Holdings (BFRG) received a second 180-day extension to meet the $1.00 bid price rule after its stock failed to recover during the initial period, signaling persistent equity market access issues. Across the filings, zero insider buying activity was detected, while all three companies share negative or mixed sentiment, pointing to a collective loss of investor and management confidence in the micro-cap space.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 19, 2026

The August 19, 2026 corporate distress landscape is dominated by acute delisting risks at two micro-cap biotech firms, Skye Bioscience and OSR Holdings, both of which received Nasdaq Staff Determinations. Skye faces a fundamental solvency crisis with negative stockholders' equity (-$497K vs. a $2.5M minimum), while OSR faces an imminent trading suspension on August 26 due to a chronic bid price deficiency, despite a massive, anomalous trading spike (370M shares on Aug 17). In contrast, Mereo BioPharma has been granted a second 180-day extension to cure its bid price deficiency, providing a longer runway until February 2027. The fourth filing, Trio-Tech International, is a voluntary, non-distressed listing transfer from NYSE American to Nasdaq, representing a neutral, administrative event. The key portfolio-level pattern is a bifurcation between companies with fundamental equity insolvency (Skye) and those with purely market-price-driven compliance issues (OSR, Mereo), with the former presenting a materially higher risk of permanent delisting. Insider activity data was absent from all filings, limiting conviction signals, but the forward-looking data creates a clear catalyst calendar of hearings and deadlines.

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 18, 2026

The August 18, 2026 filings reveal a concentrated wave of corporate distress signals across three US public companies, all involving delisting or cessation of trading. Firsthand Technology Value Fund (SVVC) is pursuing a complete wind-down and liquidation after withdrawing its BDC status, with all independent directors resigning, signaling a terminal event. CID Holdco (DAICW) faces a dual crisis: a second Nasdaq delisting notice for failing to meet market value requirements and a lender default demanding over $1 million with foreclosure threats, indicating severe financial distress. Offerpad Solutions (OPAD) presents a contrasting, voluntary transfer from NYSE to Nasdaq, which is a neutral, strategic move rather than a distress signal. Period-over-period data was not available in the filings, limiting trend analysis, but the insider resignations at SVVC and the loan default at CID Holdco are critical negative signals. The overarching theme is a bifurcation between forced exits (SVVC, CID Holdco) and strategic listing changes (OPAD), with the former two representing high-probability bankruptcy or liquidation scenarios.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 17, 2026

The digest focuses on two US public companies showing significant distress signals, with one filing new and one carried over. Nexalin Technology reveals a critical, high-materiality (9/10) delisting risk from a Nasdaq stockholders' equity deficiency ($1.5M vs. $2.5M requirement) compounded by an existing bid price appeal, posing an immediate threat to liquidity and market access. Conversely, Cloudastructure, with a mixed sentiment filing (7/10), shows a classic growth-at-a-loss profile: subscription revenue surged 164% YoY and now dominates the mix (62%), but total revenue grew only 13% as hardware sales collapsed, and operating losses widened to $2.7M. While Nexalin presents a clear liquidation or restructuring risk, Cloudastructure's path to profitability is uncertain given rising expenses and cash burn. No positive sector themes emerge; both cases highlight heightened capital market scrutiny on small-cap, cash-burning entities. The aggregate period-over-period trend is one of deteriorating financial health and elevated delisting risk.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 14, 2026

On August 14, 2026, seven US public companies filed delisting notices, creating a dramatic cluster of corporate distress signals within a single 24-hour period. All filings are under Item 3.01 (failure to satisfy a continued listing rule or standard), with four (Adagio Medical, REED'S, Optimum Communications, Teads Holding) lacking any specific reason for delisting and no financial or forward-looking guidance, amplifying investor uncertainty. SES AI Corp's partial delisting of only its public warrants (SES WS) due to 'abnormally low selling price' stands out as a nuanced event, while Worksport Ltd and Actinium Pharmaceuticals carry critical-to-high risk designations. The compressed timing and lack of quantified financial impact across all filings suggest a sector-agnostic liquidity or compliance crisis, with the average materiality score of 8.6/10 underscoring portfolio-level risk. No positive period-over-period trends, insider activity, or capital allocation data were available, reinforcing a uniformly bearish and opaque distress environment.

7 high priority 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 12, 2026

Both filings on August 12, 2026, reveal acute distress in micro-cap companies listed on Nasdaq, with CID Holdco (Dot Ai) and Generation Income Properties facing imminent delisting due to market value and bid price deficiencies. The common theme is a failure to maintain minimum listing standards despite prior compliance efforts, signaling severe liquidity and market confidence issues. CID Holdco's stock has collapsed in value, failing to meet the $50M MVLS threshold, while Generation Income Properties cannot sustain a $1.00 bid price and now faces a compounding equity deficiency. Neither company has shown any period-over-period revenue growth or margin improvement in the enriched data, and both lack insider buying or positive forward guidance, reinforcing a bearish outlook. The market implications are binary: delisting would likely trigger further price declines and loss of institutional access. These cases highlight a broader trend of struggling micro-caps unable to reverse valuation erosion in a selective market environment.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 11, 2026

The two filings in this stream both signal acute corporate distress, with one company facing imminent delisting and the other executing a radical pivot after abandoning its core business. Grove Collaborative Holdings received a NYSE non-compliance notice for failing to meet the $50 million minimum market capitalization and stockholders' equity thresholds, a classic precursor to delisting if a remediation plan is not accepted within 45 days. Hoth Therapeutics (now Rocket One Inc.) is simultaneously celebrating a strategic pivot into AI and space computing while disclosing a Nasdaq delisting notice and the fact that its licensed technologies remain pre-commercial, requiring substantial additional capital. The common theme is a severe erosion of market confidence and financial viability, with both companies trading at risk of losing their exchange listings. No period-over-period financial comparisons, insider trading activity, or capital allocation data were available in the enriched filings, limiting quantitative trend analysis but reinforcing the qualitative distress signals. The market implication is clear: both securities carry extreme downside risk from delisting, and any recovery thesis depends on improbable regulatory or operational turnarounds.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 10, 2026

This digest covers five US SEC filings, all flagged for corporate distress signals. The dominant theme is Nasdaq non-compliance and delisting risk, with three companies (Arcadia Biosciences, Lexaria Bioscience, and Northann Corp.) receiving explicit notices. A fourth, Construction Partners, faces a governance-related compliance issue. The fifth, Faraday Future, has resolved its bid price deficiency but remains in a precarious financial state. Period-over-period comparisons were largely absent from these filings, limiting trend analysis; however, the filings reveal a severe lack of liquidity and governance failures. The most critical development is the absence of remediation plans from Lexaria and Northann, suggesting a high probability of actual delisting. The market implications are significant: investors face potential total losses in companies unable to cure deficiencies, while others may see dilution from reverse stock splits. A portfolio-level pattern is the concentration of distress in micro-cap and pre-revenue companies, where cash burn and governance lapses are acute.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 07, 2026

This digest of 9 US SEC filings from August 7, 2026, reveals a surge in corporate distress signals across micro-cap stocks listed on the Nasdaq. A dominant theme is the widespread failure to maintain minimum bid prices and market value of listed securities (MVLS), with six out of nine filings (GIFTIFY, Avalanche, Neonode, Eightco, Barfresh, and Triller) directly addressing these deficiencies. This suggests a systemic liquidity and valuation crisis among companies with market caps likely below $50 million. More severe distress is evident in HeartSciences, which reported a critically low stockholders' equity of just $226,060 against a $2.5 million requirement and is tying its survival to an all-stock merger. The highest-risk event is NusaTrip's imminent delisting without appeal, linked to an SEC trading suspension and its majority owner's Chapter 11 bankruptcy. Period-over-period comparisons, while often unavailable due to 8-K filings, show deteriorating cash positions and mounting losses from annual reports, and a 'mixed' sentiment in Triller's filing underscores that compliance can be fragile. The aggregate intelligence points to a sector-wide shakeout where micro-cap companies are running out of financing options, with insider selling or silence and pending reverse split proposals adding further pressure. The key catalyst calendar is packed with compliance deadlines in early 2027, making these names high-risk, high-surveillance plays for distressed investors.

9 high priority 9 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 06, 2026

The two filings in this corporate distress digest both involve Nasdaq non-compliance issues, highlighting a common theme of small-cap companies struggling with exchange listing requirements. Olenox Industries (formerly Safe & Green Holdings) resolved its periodic filing delinquency, receiving a positive confirmation from Nasdaq after filing overdue 10-K and 10-Q reports, signaling a potential turnaround. In contrast, Accuray Inc. was forced to transfer its listing to the Nasdaq Capital Market due to a persistent bid price deficiency below $1.00, receiving a 180-day extension to February 2027 to regain compliance. While Olenox's resolution removes an immediate overhang, Accuray's situation remains precarious with no near-term catalyst for price recovery. The absence of enriched period-over-period data, insider activity, or forward-looking guidance in both filings limits quantitative trend analysis, but the qualitative distress signals are clear: one company is emerging from delinquency, while the other faces ongoing price-based delisting risk.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 05, 2026

On August 5, 2026, four US-listed companies filed 8-Ks disclosing critical corporate distress signals, with three facing imminent or potential delisting and one narrowly avoiding it. The filings reveal a severe liquidity and market access crisis in the small-cap biotech and software sectors, with Vistagen Therapeutics and Destination XL Group both confirming actual delistings due to failed continued listing standards, while Upland Software received a 180-day cure period for failing the $15M minimum market value of publicly held shares requirement. Genprex, Inc. represents a temporary reprieve, having regained Nasdaq compliance but under strict conditions requiring daily maintenance of a $1.00 bid price through December 7, 2026. The aggregate pattern shows zero insider buying across all four filings, no forward-looking guidance, and no capital allocation actions (dividends, buybacks), indicating management teams are in survival mode rather than growth mode. The concentration of distress events on a single filing date suggests potential systemic stress in micro-cap listings, with all four companies sharing characteristics of low market capitalization, negative sentiment, and high materiality scores (8-9/10).

4 high priority 4 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 04, 2026

The two filings in this stream present a stark contrast in corporate distress trajectories. Bed Bath & Beyond (BBBY) shows a classic turnaround story with its second consecutive quarter of revenue growth (+28% YoY) and a 47% surge in active customers, yet its net loss widened to -$39M from -$19M YoY, and Adjusted EBITDA deteriorated to -$12M, signaling that growth is not yet profitable. The company's transformation into Neighborhood Intelligence and planned Nasdaq listing under ticker NXH suggests a strategic pivot, but the widening losses and ballooning Technology & G&A expenses (+$45M YoY) raise concerns about cost control. Meanwhile, VSEE Health faces an imminent delisting crisis, with a Nasdaq Staff Determination triggered by a bid price of $0.10 or less for ten consecutive days, leading to a trading suspension on August 6, 2026. The company's appeal window is open but offers no stay of execution, making this a high-probability delisting event. The period-over-period data shows no revenue or margin improvements for VSEE, and the lack of any forward-looking guidance or insider activity underscores a dire liquidity situation. The overarching theme is that top-line recovery alone does not equate to financial health, and the market is punishing companies with unsustainable cash burns and low stock prices.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — August 03, 2026

Hughes Satellite Systems Corp and certain U.S. subsidiaries have filed for Chapter 11 bankruptcy in the Southern District of Texas, marking a significant corporate distress event in the satellite communications sector. The filing is driven by the need to restructure maturing secured and unsecured debt, while the company intends to refocus operations on B2B, government, and defense markets. Critically, EchoStar Corporation and Hughes' international subsidiaries are excluded from the filing, and the company has sufficient near-term liquidity to continue serving customers during the process. The filing has no impact on EchoStar's other brands (DISH TV, Sling TV, Boost Mobile), but it signals deep financial strain within the legacy satellite business. The company has engaged White & Case LLP as legal counsel and FTI Consulting as financial advisor, indicating a structured restructuring process. This event underscores the ongoing challenges in the satellite and telecom sector, particularly for companies with high debt loads and maturing obligations.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 31, 2026

On July 31, 2026, a concentrated wave of eight Nasdaq-listed micro-cap companies filed 8-Ks revealing they have fallen below the $1.00 minimum bid price, triggering deficiency notices and potential delisting. This cluster represents a significant distress signal for the small-cap biotech and healthcare sector, with all eight companies facing 180-day cure periods expiring between January 25 and January 27, 2027. Notably, bioAffinity Technologies faces an accelerated risk as it is ineligible for a standard cure period due to a prior reverse stock split, and must appeal by August 6, 2026, to avoid immediate delisting. The filings show no insider buying or positive forward guidance to offset the distress, and several companies (DocGo, PDS Biotechnology, Context Therapeutics) are explicitly considering reverse stock splits—a historically value-destructive measure. The uniformity of the distress across these filings suggests a broader market rotation away from speculative micro-cap equities, with no positive period-over-period trends or capital allocation signals to provide a counter-narrative. The most critical development is the impending August 6 appeal deadline for bioAffinity, which will serve as a bellwether for the group's ability to navigate Nasdaq's listing standards.

8 high priority 8 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 30, 2026

This digest reveals a concentrated wave of distress signals across US-listed micro-cap equities, with 4 out of 5 filings detailing imminent delisting risks due to non-compliance with minimum bid price rules. The cluster of Nasdaq and NYSE deficiency notices received within a single week (July 24-29, 2026) indicates a systemic liquidity and valuation crisis among small-cap companies, rather than isolated incidents. A critical pattern emerges: while companies like Curis have technically regained compliance, they face a Draconian 'one-year Discretionary Panel Monitor' with zero tolerance for future deficiencies, effectively placing them on a permanent watchlist. The most severe case is Woodbridge Liquidation Trust, which has formally acknowledged it cannot complete its liquidation by the original deadline, seeking a three-year extension to 2030 due to a lingering construction defect claim, signaling a deeply impaired asset recovery process. The data shows no positive period-over-period trends or insider buying to offset these bearish signals; the dominant themes are capital structure erosion, regulatory overhang, and a lack of credible turnaround catalysts. The market implication is clear: these securities face a high probability of structural impairment, with delisting representing a catastrophic loss of liquidity and access to public capital markets.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 29, 2026

All five filings in this digest are Nasdaq/NYSE listing deficiency notices, creating a concentrated thematic cluster of micro-cap and distressed equities facing imminent delisting. The common thread is a severe erosion of market confidence, with each company failing to maintain either minimum bid price ($1.00) or minimum market value of listed securities ($1M-$50M thresholds). The period-over-period data, while not explicitly provided in the filings, is implied by the 30-consecutive-day trading patterns that triggered the notices, suggesting sustained price declines. No insider trading activity, capital allocation changes, or forward-looking guidance were reported in these 8-Ks, which is notable as it signals management may be in a reactive, rather than proactive, stance. The most critical development is the simultaneous clustering of four new deficiency notices within a single week (July 22-24, 2026), suggesting a broader market rotation away from speculative, pre-revenue, or cash-burning business models. The market implication is clear: investors should expect a wave of over-the-counter (OTC) migrations or reverse stock splits as these companies scramble to maintain exchange listings, with SCWorx and Loop Industries facing the most acute multi-factor compliance challenges.

5 high priority 5 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 27, 2026

The July 27, 2026, corporate distress landscape is dominated by acute delisting threats across three micro-cap companies, signaling a severe liquidity and market access crisis in the sector. AMASS Brands and Nexalin Technology both received Nasdaq deficiency notices, with Nexalin facing an imminent trading suspension on August 4, 2026, unless a hearing panel intervenes. Picard Medical, while also in distress with negative stockholders' equity, has secured a temporary reprieve via an accepted NYSE American compliance plan, offering a potential turnaround path. Period-over-period data reveals a stark contrast in financial trajectories: Nexalin's revenue declined 12% YoY with gross margins compressing 300 bps, while Picard Medical's revenue grew 8% YoY but was offset by a 15% YoY increase in operating losses. No insider trading activity was reported across the three filings, suggesting management may be constrained by lock-ups or a lack of confidence. The overarching theme is a binary risk-reward profile for distressed micro-caps, where regulatory forbearance is the only lifeline separating continued listing from a catastrophic delisting event.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 24, 2026

This digest captures a severe wave of corporate distress across 18 US-listed companies, predominantly driven by Nasdaq and NYSE minimum bid price and market value deficiencies. The most critical development is the confirmed Chapter 11 plan for QVC Inc. and QVC Group, where all existing equity will be canceled for no consideration, representing a total loss for shareholders. A staggering 14 out of 18 filings involve delisting or non-compliance notices, with 12 specifically for sub-$1.00 bid prices, indicating a systemic liquidity and valuation crisis among small-cap and micro-cap names. The biotech and tech sectors are disproportionately affected, with 6 biotech/life sciences firms and 4 tech companies facing imminent listing threats. Insider activity data is sparse, but the absence of insider buying in the face of these distress signals is a notable bearish indicator. The QVC bankruptcy is the highest materiality event (10/10), while the cluster of bid price deficiencies creates a calendar of critical compliance deadlines between July 2026 and January 2027.

18 high priority 18 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 24, 2026

Both filings concern the same bankruptcy event: QVC Inc. and its parent QVC Group Inc. received court confirmation of their prepackaged Chapter 11 plan on July 20, 2026. The plan wipes out all existing equity (common and preferred) for zero consideration, while secured noteholders receive new equity, cash, and takeback debt. Trade and unsecured claims are to be paid in full, and the company expects to emerge from bankruptcy after satisfying conditions precedent. The filings are materially identical, with QVC Group's 8-K adding detail on the issuance of 50 million new common shares. The negative sentiment and maximum materiality (10/10) reflect a total loss for equity holders but a structured recovery for creditors, signaling a high-risk, high-conviction restructuring event.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 23, 2026

This intelligence digest covers five SEC 8-K filings from July 23, 2026, all involving Nasdaq compliance issues and acute corporate distress. The filings are dominated by three distinct distress signals: two companies (Nuvve, Fly-E Group) are delinquent on periodic reports (10-Q/10-K), three (Nuvve, Aprea Therapeutics, InspireMD) fail the $1.00 minimum bid price rule, and one (Shore Bancshares) faces audit committee independence violations. The most severe case is Nuvve Holding Corp., which faces an immediate trading suspension and transition to the OTC Pink market due to compounding non-compliance with three separate listing rules, signaling a high probability of equity value destruction. Across the group, no company reported revenue growth or positive forward guidance; the distress is wholly structural and regulatory. The presence of multiple delisting notices in a single day underscores a tightening enforcement environment by Nasdaq, potentially signaling broader market stress that may push more micro-cap issuers into non-compliance. The only partial reprieve is Fly-E Group, which filed its overdue 10-K on the same day as its notice, likely curing the deficiency. Investors should treat nearly all these companies as high-risk, with Nuvve being a near-certain loss of exchange listing and likely total equity impairment.

5 high priority 5 total filings